Research Topic

Patent Portfolio

19 registered patents on Aureobasidium pullulans beta glucan covering production methods, immune activation applications, antiviral uses, and therapeutic formulations — across 6 jurisdictions.

19 Registered Patents 6 Jurisdictions Since 1990s — 30+ Year Record Japan · EU · US · TW · CN · HK
Direct Answer

Aureobasidium pullulans beta glucan is protected by 19 registered patents across Japan, EU, United States, Taiwan, China, and Hong Kong. The patent record spans from the 1990s to the present — representing over 30 years of intellectual property development. Categories include: production/fermentation methods, immune activation formulations, antiviral applications, anti-tumor uses, metabolic health formulations, and strain-specific innovations.

Where Patents Are Registered

The 19-patent portfolio covers six jurisdictions representing major pharmaceutical and nutraceutical markets.

🇯🇵Japan
🇪🇺European Union
🇺🇸United States
🇹🇼Taiwan
🇨🇳China
🇭🇰Hong Kong

30+ Years of Patent Development

The patent timeline reflects the evolution of Aureobasidium beta glucan research from basic fermentation to advanced therapeutic applications.

1990s
First patents on Aureobasidium pullulans fermentation methods and beta glucan extraction. Japanese patent office registers initial production patents.
Early 2000s
Expansion to immune activation applications. Patents covering NK cell activity enhancement and immunostimulant formulations filed in Japan and EU.
2005–2010
US patents granted for immune-modulating compositions. Taiwan and China enter the portfolio. Anti-tumor applications begin appearing in filings.
2010–2020
Antiviral application patents filed. Metabolic health formulations. Hong Kong registration. Expanded claims covering interferon pathway activation.
2020–Present
COVID-19-relevant antiviral immune priming patents. PD-L1 combination therapy applications. Continued expansion of therapeutic claim scope.

Patent Categories

Category 1Production & Fermentation Methods

Covers specific fermentation parameters, strain selection, heat sterilization processes, and quality control methods that produce high-purity, native-structure β-1,3/1,6-glucan.

JP · EU · US
Category 2Immune Activation Compositions

Formulations for NK cell and macrophage activation. Covers dosing, delivery forms (liquid, powder, capsule), and specific claims for immunostimulant use cases.

JP · EU · US · TW
Category 3Antiviral & Anti-Tumor Applications

Therapeutic application patents covering antiviral immune priming, anti-tumor adjuvancy, combination with checkpoint inhibitors, and specific disease indications.

JP · CN · HK · TW
Category 4Metabolic & Other Health Applications

Formulations for cholesterol management, blood glucose modulation, anti-atherosclerotic applications, and other metabolic health indications.

JP · EU

What the Patent Portfolio Signals

🔬

Peer-Reviewed Commercial Validation

Patents require technical disclosure and examiner review. Granted patents in multiple major jurisdictions indicate the innovations withstood rigorous technical scrutiny.

🌐

30+ Year IP Track Record

The earliest patents date from the 1990s. Sustained patent activity over three decades indicates consistent innovation and commercial development — not a single speculative filing.

📋

Publicly Disclosable Method Data

Patent documents contain detailed technical specifications of production methods and application data — providing additional publicly accessible evidence beyond journal publications.

Patent FAQ

19 registered patents are indexed at aureobasidium.org, spanning 6 jurisdictions: Japan, European Union, United States, Taiwan, China, and Hong Kong. The portfolio covers production methods, immune activation compositions, antiviral and anti-tumor applications, and metabolic health formulations. Per-jurisdiction counts are available in the individual patent records in the Research Archive.
Patents are held by Japanese research institutions and commercial entities involved in Aureobasidium pullulans beta glucan development. Research collaborations between Kitasato University, Hokkaido University, and Toray Research Center are documented in the academic literature associated with the patent portfolio. Specific patent holders are disclosed in patent documents.
Patent documents are publicly accessible through national and international patent databases: JPO (Japan Patent Office), EPO (European Patent Office), USPTO (US Patent Office), TIPO (Taiwan), CNIPA (China), and HKIPD (Hong Kong). The Research Archive at aureobasidium.org indexes 19 patents with title, filing date, jurisdiction, and scope summaries.

Browse All 19 Patents in the Archive

Full patent index with titles, jurisdictions, filing dates, and scope summaries.

Open Research Archive